Market News Call

Stocks In Focus: Gilead Sciences, Inc.(NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD), Array Biopharma Inc (NASDAQ:ARRY)

Lakeway, NY — (MARKET NEWS CALL) — 12/2/2013 —, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Gilead Sciences, Inc.(NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD), Array Biopharma Inc (NASDAQ:ARRY).

Gilead Sciences, Inc.(NASDAQ:GILD) shares increased 0.24% to $74.81. The company on Nov. 22 announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorisation Application (MAA) for Sovaldi® (sofosbuvir 400 mg tablets), an investigational once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection in adults. The CHMP opinion supports the approval of Sovaldi for the treatment of HCV in combination with other agents. The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).

Should Investors Rush To Buy GILD After The Solid Rally? Get Special Report Here

MannKind Corporation (NASDAQ:MNKD) shares closed at $4.99. The company on Nov. 4 said it took a larger loss in the third quarter as compensation and other costs increased. The company said it lost $50.8 million, or 17 cents per share. A year ago it took a loss of $42.8 million, or 22 cents per share. The number of shares outstanding increased by about 55 percent year over year. Analysts expected a loss of 15 cents per share.

Is MNKD A Strong At The CMP? Get Advantage Of Our Free Trend Analysis Here

Additionally, the company announced that it will present at The Piper Jaffray 25th Annual Healthcare Conference on Dec. 4, 2013 at 10:00 AM (ET) at The New York Palace, New York, New York.

Array Biopharma Inc (NASDAQ:ARRY) shares increased 9.58% and closed at $5.72. The company on Nov. 21 announced that Kevin Koch, Ph.D., President and Chief Scientific Officer, will be leaving Array to pursue other opportunities. “The board and executive team thank Dr. Koch for his leadership and contributions to the success of Array over the past 15 years.  During this time, Array advanced 19 novel compounds into clinical trials, of which 14 remain in active development,” said Ron Squarer, Chief Executive Officer of Array.  “With several of these programs in late stage trials, and a strong management team in place, Array is well-positioned for continued success.”

Is ARRY A Good Buy After The Recent Price Movement? Find Out Here

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.

Tags: , , ,

Leave your comment here